TGTX Tg Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TGTX

Price (delayed)

$56

Market cap

$8.57B

P/E Ratio

18.18

Dividend/share

N/A

EPS

$3.08

Enterprise value

$8.84B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 97

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active ...

Highlights
The equity has surged by 119% year-on-year and by 3.6% since the previous quarter
The revenue has soared by 76% YoY and by 14% QoQ
The quick ratio has decreased by 27% QoQ but it has increased by 26% YoY
TGTX's debt has soared by 198% YoY
The P/E is 52% higher than the last 4 quarters average of 12.4
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tgtherapeutics.com
Peers: ALKS NERV

Key stats

What are the main financial stats of TGTX

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
-3.63%
1 week
0.27%
1 month
3.19%
1 year
57.44%
YTD
87.86%
QTD
1.93%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$799.54M
Gross profit
$658.6M
Operating income
$136.33M
Net income
$441.49M
Gross margin
82.4%
Net margin
55.2%
The revenue has soared by 76% YoY and by 14% QoQ
Tg Therapeutics's gross profit has surged by 67% YoY and by 13% QoQ
The operating income has soared by 59% YoY but it has contracted by 9% from the previous quarter
Tg Therapeutics's operating margin has decreased by 20% QoQ and by 10% YoY

Price vs fundamentals

How does TGTX's price correlate with its fundamentals

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
TGTX P/E details
P/E
18.18
P/B
14.19
P/S
9.93
EV/EBIT
63.56
EV/EBITDA
63.5
EV/Sales
11.06
The P/E is 52% higher than the last 4 quarters average of 12.4
Tg Therapeutics's EPS has decreased by 4.3% QoQ
The equity has surged by 119% year-on-year and by 3.6% since the previous quarter
The P/B is 49% above the last 4 quarters average of 9.9 but 31% below the 5-year quarterly average of 21.5
The P/S is 93% below the 5-year quarterly average of 143.2 but 23% above the last 4 quarters average of 8.4
The revenue has soared by 76% YoY and by 14% QoQ

Efficiency

How efficient is Tg Therapeutics business performance
The company's return on equity has surged by 177% YoY but it fell by 17% QoQ
TGTX's ROIC is down by 38% YoY and by 24% QoQ
The ROA has contracted by 21% from the previous quarter
Tg Therapeutics's return on sales has decreased by 19% YoY and by 19% QoQ

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The total assets is 58% higher than the total liabilities
Tg Therapeutics's total liabilities has surged by 143% YoY and by 9% QoQ
The total assets has soared by 133% YoY and by 7% QoQ
TGTX's debt is 25% higher than its equity
TGTX's debt has soared by 198% YoY
The equity has surged by 119% year-on-year and by 3.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.